{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:53:38Z","timestamp":1791158018314,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Disease-a-Month"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.disamonth.2008.09.002","type":"journal-article","created":{"date-parts":[[2008,11,10]],"date-time":"2008-11-10T02:34:57Z","timestamp":1226284497000},"page":"793-800","source":"Crossref","is-referenced-by-count":21,"title":["Antimicrobial Agents in Treatment of MRSA Infections"],"prefix":"10.1016","volume":"54","author":[{"given":"Mark D.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine F.","family":"Decker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.disamonth.2008.09.002_bib1","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1056\/NEJMcp070747","article-title":"Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.","volume":"357","author":"Daum","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.disamonth.2008.09.002_bib2","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1086\/529445","article-title":"Current treatment options for community-acquired methicillin-resistant Staphylococcus aureus infection","volume":"46","author":"Moellering","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.disamonth.2008.09.002_bib3","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1086\/511884","article-title":"The role of ancillary antimicrobial therapy for treatment of uncomplicated skin infections in the era of community-associated methicillin-resistant Staphylococcus aureus.","volume":"44","author":"Gorwitz","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.disamonth.2008.09.002_bib4","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3201\/eid0702.010204","article-title":"The changing epidemiology of Staphylococcus aureus.","volume":"7","author":"Chamber","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.disamonth.2008.09.002_bib5","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/jac\/dkl283","article-title":"Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus.","volume":"58","author":"Kaka","year":"2006","journal-title":"J Antimicrob Chemo"},{"key":"10.1016\/j.disamonth.2008.09.002_bib6","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa043252","article-title":"Methicillin-resistant Staphylococcus aureus disease in three communities","volume":"352","author":"Fridkin","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.disamonth.2008.09.002_bib7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1592\/phco.25.2.253.56956","article-title":"Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus.","volume":"25","author":"Grim","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.disamonth.2008.09.002_bib8","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1345\/aph.1D156","article-title":"Trimethoprim\/sulfamethoxazole for treatment of severe Staphylococcus aureus infections","volume":"38","author":"Adra","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.disamonth.2008.09.002_bib9","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1086\/525536","article-title":"Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection","volume":"46","author":"Proctor","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.disamonth.2008.09.002_bib10","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1128\/JCM.02274-06","article-title":"High frequencies of clindamycin and tetracycline resistance methicillin-resistant Staphylococcus aureus pulsed-field tpe USA300 isolates collected at a Boston ambulatory health center","volume":"45","author":"Han","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.disamonth.2008.09.002_bib11","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1128\/AAC.00262-07","article-title":"Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus.","volume":"51","author":"Ruhe","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.disamonth.2008.09.002_bib12","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1128\/AAC.00206-07","article-title":"Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus.","volume":"51","author":"Cenizal","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.disamonth.2008.09.002_bib13","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1086\/426894","article-title":"Inducible clindamycin resistance in Staphylococci: should clinicians and microbiologists be concerned?","volume":"40","author":"Lewis","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.disamonth.2008.09.002_bib14","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.inf.0000073163.37519.ee","article-title":"Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children","volume":"22","author":"Martinez-Aguilar","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.disamonth.2008.09.002_bib15","series-title":"40th Annual Meeting of the Infectious Diseases Society of America, Chicago, October 24-27, 2002","article-title":"A multistate study of the epidemiology of community-onset methicillin-resistant Staphylococcus aureus [Abstract 121]","author":"Hageman","year":"2002"},{"key":"10.1016\/j.disamonth.2008.09.002_bib16","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1086\/510396","article-title":"Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus.","volume":"195","author":"Stevens","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.disamonth.2008.09.002_bib17","first-page":"565","article-title":"Staphylococcus aureus resistant to vancomycin: United States, 2002","volume":"51","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.disamonth.2008.09.002_bib18","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.1086\/533592","article-title":"Increasing antibiotics resistance among methicillin-resistant Staphylococcus aureus strains","volume":"46","author":"Sakoulas","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.disamonth.2008.09.002_bib19","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","article-title":"High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity","volume":"166","author":"Hidayat","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.disamonth.2008.09.002_bib20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/00000441-200508000-00007","article-title":"Clinical characteristics of linezolid-resistant Staphylococcus aureus infections","volume":"330","author":"Peeters","year":"2005","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.disamonth.2008.09.002_bib21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(01)05410-1","article-title":"Linezolid resistance in a clinical isolate of Staphylococcus aureus.","volume":"358","author":"Tsiodras","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.disamonth.2008.09.002_bib22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1055\/s-2006-933677","article-title":"Methicillin-resistant S. aureus ventilator-associated pneumonia: strategies to prevent and treat","volume":"27","author":"Lam","year":"2006","journal-title":"Sem Resp Crit Care Med"},{"key":"10.1016\/j.disamonth.2008.09.002_bib23","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/01.CCM.0000168206.59873.80","article-title":"Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia","volume":"33","author":"Boselli","year":"2005","journal-title":"Crit Care Med"},{"key":"10.1016\/j.disamonth.2008.09.002_bib24","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1378\/chest.124.5.1789","article-title":"Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia","volume":"124","author":"Wunderink","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.disamonth.2008.09.002_bib25","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1086\/504809","article-title":"Linezolid and serotonergic drug interactions: a retrospective survey","volume":"43","author":"Taylor","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.disamonth.2008.09.002_bib26","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1517\/13543784.8.8.1223","article-title":"Daptomycin: a novel agent for gram-positive infections","volume":"8","author":"Tally","year":"1999","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.disamonth.2008.09.002_bib27","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1086\/428616","article-title":"Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia","volume":"40","author":"Mangili","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.disamonth.2008.09.002_bib28","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.disamonth.2008.09.002_bib29","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1086\/430352","article-title":"Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact","volume":"191","author":"Silverman","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.disamonth.2008.09.002_bib30","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1128\/AAC.00202-07","article-title":"Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF","volume":"51","author":"Pillai","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.disamonth.2008.09.002_bib31","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1128\/AAC.50.3.1079-1082.2006","article-title":"Correlation between reduced daptomycin susceptibility and vancomycin resistance in Vancomycin-Intermediate Staphylococcus aureus.","volume":"50","author":"Cui","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.disamonth.2008.09.002_bib32","article-title":"Cubist Pharmaceuticals","year":"2003","journal-title":"Cubicin (daptomycin for injection) product information"},{"key":"10.1016\/j.disamonth.2008.09.002_bib33","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1086\/505494","article-title":"Tigecycline: a critical analysis","volume":"43","author":"Stein","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.disamonth.2008.09.002_bib34","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/jac\/dkl403","article-title":"Serum, tissue, and body fluid concentrations of tigecycline after a single 100 mg dose","volume":"58","author":"Rodvold","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.disamonth.2008.09.002_bib35","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1086\/587896","article-title":"Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms","volume":"46","author":"Stryjewski","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.disamonth.2008.09.002_bib36","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1517\/13543784.16.3.347","article-title":"Telavancin: a novel lipoglycopeptide for serious gram-positive infections","volume":"16","author":"Laohavaleeson","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.disamonth.2008.09.002_bib37","doi-asserted-by":"crossref","first-page":"S386","DOI":"10.1086\/533595","article-title":"Management of methicillin-resistant Staphylococcus aureus bacteremia","volume":"46","author":"Cosgrove","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.disamonth.2008.09.002_bib38","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1086\/519471","article-title":"Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections","volume":"45","author":"Micek","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.disamonth.2008.09.002_bib39","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/587673","article-title":"The deadly toll of invasive methicillin-resistant Staphylococcus aureus infection in community hospitals","volume":"46","author":"Kaye","year":"2008","journal-title":"Clin Infect Dis"}],"container-title":["Disease-a-Month"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502908001168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502908001168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,24]],"date-time":"2018-12-24T09:58:17Z","timestamp":1545645497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011502908001168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0011502908001168"],"URL":"https:\/\/doi.org\/10.1016\/j.disamonth.2008.09.002","relation":{},"ISSN":["0011-5029"],"issn-type":[{"value":"0011-5029","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}